Answers are grounded in this paper and cite their sources.
Neoadjuvant chemoimmunotherapy improves outcomes in resectable non–small cell lung cancer, yet pathologic response incompletely predicts durability of benefit. Spatial profiling using resected tumors and lymph nodes revealed distinct immune subtypes and identified a gene signature associated with improved outcomes, providing a framework for biomarker-guided treatment selection and prospective validation.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: